The Covance Immunology and Immunotoxicology (I&I) team offer integrated programs, state-of-the-art technology and deep scientific and technical Immunology & Immunotoxicology expertise for the development of safe therapeutic molecules in respect to global regulatory requirements and regulations.
With six sites spread across three continents, the Covance I&I team has been constantly expanding over the years, strategically incorporating partners to strengthen its capacity to cover all aspects of drug development, from in-vitro testing to pre-clinical and clinical trial testing, using a broad range of biological samples, from human subjects to a variety of animal models.
Our research activities are tailored for therapeutic molecules and make use of a wide array of techniques and state-of-the-art technologies that include multi-colour flow cytometry, immunoassay biomarker techniques and cell based in-vitro assays.
Role within Project
- Development of in vitro assay
- Building physiologically relevant assays for measuring the potential of cytokine storm response
- Development and validation Immune-competent organotypic and microphysioloical system (e.g. Organ on a chip)
BOEC system – building an autologous system that mimics the interaction of PBMCs and the endothelium
- Provide expertise and knowledge from previous pre-clinical studies
- Support of immune-oncology models check point inhibitors
- Drive for new regulatory direction
- Provide regulatory experience and guidance for development and validation of novel biomarkers